Meeting
2016 Gastrointestinal Cancers Symposium
Adding targeted inhibition of PI3K and MAPK signaling pathways to standard chemotherapy in experimental pancreatic cancer.
Authors
Niranjan Awasthi
Indiana University School of Medicine, South Bend, IN
Niranjan Awasthi , Margaret A. Schwarz , Roderich Schwarz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 278)
DOI
10.1200/jco.2016.34.4_suppl.278
Abstract #
278
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer.
First Author: Ursula Matulonis
Poster
2024 ASCO Genitourinary Cancers Symposium
MAPK pathway alterations as a targetable vulnerability in bladder cancer.
First Author: Vincent D'Andrea
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic indicators of KRAS G12X mutations in pancreatic cancer.
First Author: Bach Ardalan
Poster
2020 ASCO Virtual Scientific Program
Phase I study of afatinib plus selumetinib in patients with KRAS mutation-positive colorectal, non-small cell lung and pancreatic cancer.
First Author: Sanne Huijberts